Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for "intermediate risk"

Paul M Ridker; Jean G Macfadyen; Børge G Nordestgaard; Wolfgang Koenig; John J P Kastelein; Jacques Genest; Robert J Glynn

doi:10.1161/CIRCOUTCOMES.110.938118

Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for "intermediate risk"

Paul M Ridker, Jean G Macfadyen, Børge G Nordestgaard, Wolfgang Koenig, John J P Kastelein, Jacques Genest, Robert J Glynn

61 Citations (Scopus)

Abstract

Recent primary prevention guidelines issued in Canada endorse the use of statin therapy among individuals at "intermediate risk" who have elevated levels of high-sensitivity C-reactive protein (hsCRP). However, trial data directly addressing whether this recommendation defines a patient population in which statin therapy is effective have not previously been published.

Original language	English
Journal	Circulation. Cardiovascular Quality and Outcomes
Volume	3
Issue number	5
Pages (from-to)	447-52
Number of pages	6
ISSN	1941-7713
DOIs	https://doi.org/10.1161/CIRCOUTCOMES.110.938118
Publication status	Published - Sept 2010

Keywords

Aged
C-Reactive Protein
Canada
Cardiovascular Diseases
Cholesterol, LDL
Evidence-Based Medicine
Female
Fluorobenzenes
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Male
Middle Aged
Practice Guidelines as Topic
Primary Prevention
Pyrimidines
Risk
Sulfonamides
Treatment Outcome

Access to Document

10.1161/CIRCOUTCOMES.110.938118

Fingerprint

Dive into the research topics of 'Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for "intermediate risk"'. Together they form a unique fingerprint.

Cite this

Ridker, P. M., Macfadyen, J. G., Nordestgaard, B. G., Koenig, W., Kastelein, J. J. P., Genest, J., & Glynn, R. J. (2010). Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for "intermediate risk". Circulation. Cardiovascular Quality and Outcomes, 3(5), 447-52. https://doi.org/10.1161/CIRCOUTCOMES.110.938118

Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for "intermediate risk". / Ridker, Paul M; Macfadyen, Jean G; Nordestgaard, Børge G et al.
In: Circulation. Cardiovascular Quality and Outcomes, Vol. 3, No. 5, 09.2010, p. 447-52.

Research output: Contribution to journal › Journal article › Research › peer-review

Ridker, PM, Macfadyen, JG, Nordestgaard, BG, Koenig, W, Kastelein, JJP, Genest, J & Glynn, RJ 2010, 'Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for "intermediate risk"', Circulation. Cardiovascular Quality and Outcomes, vol. 3, no. 5, pp. 447-52. https://doi.org/10.1161/CIRCOUTCOMES.110.938118

Ridker PM, Macfadyen JG, Nordestgaard BG, Koenig W, Kastelein JJP, Genest J et al. Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for "intermediate risk". Circulation. Cardiovascular Quality and Outcomes. 2010 Sept;3(5):447-52. doi: 10.1161/CIRCOUTCOMES.110.938118

Ridker, Paul M ; Macfadyen, Jean G ; Nordestgaard, Børge G et al. / Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the Justification for Use of Statins in Prevention : an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for "intermediate risk". In: Circulation. Cardiovascular Quality and Outcomes. 2010 ; Vol. 3, No. 5. pp. 447-52.

@article{3ff919b6776447a3835949b0377e252b,

title = "Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5\% to 10\% and 10\% to 20\% 10-year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for {"}intermediate risk{"}",

abstract = "Recent primary prevention guidelines issued in Canada endorse the use of statin therapy among individuals at {"}intermediate risk{"} who have elevated levels of high-sensitivity C-reactive protein (hsCRP). However, trial data directly addressing whether this recommendation defines a patient population in which statin therapy is effective have not previously been published.",

keywords = "Aged, C-Reactive Protein, Canada, Cardiovascular Diseases, Cholesterol, LDL, Evidence-Based Medicine, Female, Fluorobenzenes, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Male, Middle Aged, Practice Guidelines as Topic, Primary Prevention, Pyrimidines, Risk, Sulfonamides, Treatment Outcome",

author = "Ridker, \{Paul M\} and Macfadyen, \{Jean G\} and Nordestgaard, \{B{\o}rge G\} and Wolfgang Koenig and Kastelein, \{John J P\} and Jacques Genest and Glynn, \{Robert J\}",

year = "2010",

month = sep,

doi = "10.1161/CIRCOUTCOMES.110.938118",

language = "English",

volume = "3",

pages = "447--52",

journal = "Circulation. Cardiovascular Quality and Outcomes",

issn = "1941-7713",

publisher = "Lippincott Williams and Wilkins",

number = "5",

}

TY - JOUR

T1 - Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the Justification for Use of Statins in Prevention

T2 - an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for "intermediate risk"

AU - Ridker, Paul M

AU - Macfadyen, Jean G

AU - Nordestgaard, Børge G

AU - Koenig, Wolfgang

AU - Kastelein, John J P

AU - Genest, Jacques

AU - Glynn, Robert J

PY - 2010/9

Y1 - 2010/9

N2 - Recent primary prevention guidelines issued in Canada endorse the use of statin therapy among individuals at "intermediate risk" who have elevated levels of high-sensitivity C-reactive protein (hsCRP). However, trial data directly addressing whether this recommendation defines a patient population in which statin therapy is effective have not previously been published.

AB - Recent primary prevention guidelines issued in Canada endorse the use of statin therapy among individuals at "intermediate risk" who have elevated levels of high-sensitivity C-reactive protein (hsCRP). However, trial data directly addressing whether this recommendation defines a patient population in which statin therapy is effective have not previously been published.

KW - Aged

KW - C-Reactive Protein

KW - Canada

KW - Cardiovascular Diseases

KW - Cholesterol, LDL

KW - Evidence-Based Medicine

KW - Female

KW - Fluorobenzenes

KW - Humans

KW - Hydroxymethylglutaryl-CoA Reductase Inhibitors

KW - Male

KW - Middle Aged

KW - Practice Guidelines as Topic

KW - Primary Prevention

KW - Pyrimidines

KW - Risk

KW - Sulfonamides

KW - Treatment Outcome

UR - https://www.scopus.com/pages/publications/78650181463

U2 - 10.1161/CIRCOUTCOMES.110.938118

DO - 10.1161/CIRCOUTCOMES.110.938118

M3 - Journal article

C2 - 20736443

SN - 1941-7713

VL - 3

SP - 447

EP - 452

JO - Circulation. Cardiovascular Quality and Outcomes

JF - Circulation. Cardiovascular Quality and Outcomes

IS - 5

ER -

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this